'The Top Line' podcast: The aftermath of Roche's failed TIGIT, Big Pharma's Q1 growth vs. mRNA stars, plus this week's headlines

Anti-TIGIT drugs were once hailed as the future of immuno-oncology, but Roche's two recent clinical trial failures for tiragolumab are raising questions about whether Big Pharmas bet on the wrong horse. Also under discussion is the sector's impressive first-quarter revenue growth. Out of nearly two dozen biopharma companies, more than half generated double-digit growth, including eye-popping increases from mRNA stars Moderna and BioNTech. And Fierce journalists finally got together in person after more than two years. They share what it was like to be in a newsroom once again.

To learn more about the topics in this episode:

The Top Line is produced by senior multimedia producer Teresa Carey, with editor-in-chief Tracy Staton, managing editor Querida Anderson, senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.

To Listen to More Episodes from The Top Line